Introduction
============

Lung cancer is a leading cause of cancer death worldwide \[[@b1-crt-2018-151],[@b2-crt-2018-151]\]. In Korea, 24,000 cases are newly diagnosed, and 17,440 patients die of lung cancer each year \[[@b2-crt-2018-151]\]. Approximately 80-85% of lung cancers are classified as non-small cell lung cancer (NSCLC) \[[@b3-crt-2018-151]\]. The discovery of relevant genomic abnormalities in NSCLC has led to the development of novel, targeted chemotherapeutic agents. It has also caused a paradigm shift in the treatment of NSCLC, particularly for those with non-squamous cell carcinoma. Epidermal growth factor receptor (*EGFR*) mutations represent the most prevalent drug-treatable targets and are detected in approximately 40% of NSCLC cases in Asian patients, and in 10%-20% of cases in Caucasian patients \[[@b4-crt-2018-151],[@b5-crt-2018-151]\]. *EGFR* mutations are commonly found in never-smokers, females, and patients with adenocarcinoma. The most common activating *EGFR* mutations include an in-frame deletion in exon 19 and the L858R mutation in exon 21. Together, these account for 90% of *EGFR* mutations \[[@b6-crt-2018-151]\].

EGFR tyrosine kinase inhibitors (TKIs) are associated with a highly effective and durable response in NSCLC patients with these common *EGFR* mutations, often yielding 9-13 months of progression-free survival (PFS) and more than 24 months of overall survival (OS) \[[@b7-crt-2018-151]-[@b9-crt-2018-151]\]. Other, less commonly observed *EGFR*mutations (such as G719X or L861Q) account for 2%-3% of *EGFR* mutations and are also considered responsive to *EGFR* TKIs \[[@b10-crt-2018-151]\].

*EGFR* exon 20 insertion mutations are typically located just after the C-helix of the tyrosine kinase domain of *EGFR*, and their incidence varies between 1% to 9% of all *EGFR* mutations \[[@b11-crt-2018-151]-[@b15-crt-2018-151]\]. Given the rarity of these mutations and the fact they are mostly studied in surgically resected patients, the clinical characteristics and outcomes of advanced NSCLC patients with *EGFR* exon 20 insertion mutations have not been fully established.

Materials and Methods
=====================

1. Patients
-----------

Between January 2009 and December 2017, histologically confirmed Samsung Medical Center NSCLC patients with activating *EGFR* mutations were selected from an institutional database. Among them, patients with an *EGFR* exon 20 insertion mutation were retrospectively analyzed for clinicopathological characteristics, responses to systemic chemotherapy or targeted agents, PFS, and OS.

2. *EGFR* mutation tests
------------------------

Mutational analyses of *EGFR* (exons 18-21) were performed as previously described by directional sequencing, by the peptide nucleic acid clamp method, or by next-generation sequencing \[[@b16-crt-2018-151]\].

3. Statistical analysis
-----------------------

All available data were retrospectively collected using a standardized case report form. OS and PFS were calculated using the Kaplan-Meier method. The Cox proportional hazards regression model was used to evaluate the impact of collected variables on PFS and OS. Two-sided p-values were set at a 0.05 significance level. All analyses were performed using SPSS ver. 23.0 software (IBM Corp., Armonk, NY).

4. Ethical statement
--------------------

Institutional Review Board (IRB) approval was obtained from Samsung Medical Center (SMC, Seoul, Korea, SMC 2018-02-019). The IRB approved waiver of informed consent.

Results
=======

1. Prevalence of *EGFR* mutations
---------------------------------

From January 2009 to December 2017, 3,539 patients showed positive results in the *EGFR* mutation test. Among them, 1,712 (48.3%) had an exon 19 deletion, 1,451 (41.0%) had L858R, 132 (3.7%) had G719X, 92 (2.6%) had L861Q, 56 (1.6%) had an exon 20 insertion, and 34 (1.0%) had S768I ([S1 Fig.](#SD1-crt-2018-151){ref-type="supplementary-material"}). Among the 56 patients with an exon 20 insertion, eight had an additional mutation: four had an exon 19 deletion, two had L858R, one had G719S, and one had S768I.

Of the 3,539 total patients, 1,479 had advanced NSCLC. These patients included 752 (50.8%) with an exon 19 deletion, 557 (37.7%) with L858R, 49 (3.3%) with G719X, 49 (3.3%) with L861Q, 27 (1.8%) with an exon 20 insertion, and 17 (1.1%) with S768I ([Fig. 1](#f1-crt-2018-151){ref-type="fig"}).

2. Characteristics of patients with exon 20 insertion mutation
--------------------------------------------------------------

Among total 3,539 patients, 3,163 patients were identified that having common *EGFR* mutations, meanwhile 376 patients were uncommon *EGFR* mutations. Demographic characteristics of total 3,539 patients were summarized in [Table 1](#t1-crt-2018-151){ref-type="table"}. Women, adenocarcinoma, and early staged NSCLC patients were more common in NSCLC patients with common *EGFR* mutations.

Baseline characteristics of 27 advanced NSCLC patients harboring an exon 20 insertion mutation are summarized in [Table 2](#t2-crt-2018-151){ref-type="table"}. The median follow-up duration was 12.1 months (range, 0.9 to 62.4 months). The median age at diagnosis was 60 years (range, 43 to 75 years), and 41% of patients were female. A majority of patients (78%) were never-smokers, and most (96%) had adenocarcinoma. The most common metastatic sites were the central nervous system (40.7%), lung (33.3%), bone (33.3%), and liver (18.5%). Of note, 23 patients had only an exon 20 insertion mutation, while four patients had an additional activating mutation: two had L858R, one had S768I, and one had G719S ([Table 2](#t2-crt-2018-151){ref-type="table"}).

3. Types of exon 20 insertion mutations
---------------------------------------

Among 27 patients with exon 20 insertions, only 17 had available data for amino acid position changes. All exon 20 insertions were clustered between Val769 and Val775. His-773_Val774insHis was the most common insertion mutation (n=7, 41.2%), followed by Val774_Cys775insHisVal (n=3, 17.7%) and His773_Val774insProHis (n=2, 11.7%). Each of the following mutations was found one time: His773_Val-774insAsnProHis, Pro772_His773insThrThrPro, Pro772\_ His-773insGlyAsnPro, Val769_Asn771insValGlyVal, and Asp-770_Asn771insGly ([Table 3](#t3-crt-2018-151){ref-type="table"}).

4. Treatment responses and clinical outcomes
--------------------------------------------

Of the 27 patients with exon 20 insertions, 22 received platinum-based systemic chemotherapy. The overall response rate (ORR) was 50.0%, and the disease control rate was 77.2%. The median PFS was 4.2 months (95% confidence interval \[CI\], 1.7 to 6.6), and the median OS was 29.4 months (95% CI, 9.3 to 49.6) ([Fig. 2](#f2-crt-2018-151){ref-type="fig"}). In contrast, all patients with a double mutation were still alive at the time of last follow-up (November 15, 2017; OS range, 2.2 to 15.0 months). A Cox proportional regression analysis revealed that central nervous system metastasis was associated with poor OS (p=0.043, data not shown).

Six patients were treated with an EGFR TKI. Three patients received a reversible EGFR TKI (erlotinib), and the other three received an irreversible EGFR TKI (two received afatinib, and one received osimertinib). Among the four patients with only an exon 20 insertion, three had progressive disease and one had stable disease. In contrast, the two doublemutation patients achieved a partial response to treatment ([Table 4](#t4-crt-2018-151){ref-type="table"}).

Discussion
==========

We found that exon 20 insertion mutations represented 1.6% of all *EGFR* mutations, regardless of the cancer stage. Exon 20 insertions represented 1.8% of the *EGFR* mutations found in cases of advanced NSCLC, consistent with previous reports \[[@b6-crt-2018-151],[@b11-crt-2018-151],[@b12-crt-2018-151],[@b14-crt-2018-151]\]. These patients shared similar characteristics with patients harboring other common *EGFR* mutations in that the majority had adenocarcinoma (96%) and were never-smokers (78%).

Amino acid sequencing data from the exon 20 insertion mutations indicated that the majority (88.2%) showed changes after His773. The most frequent amino acid change was His773_Val774insHis (41.1%), followed by Val774_Cys-775insHisVal (17.6%) and His773_Val774insProHis (11.7%). All amino acid changes occurred between Val769 and Val-775, in a region located just after the C-helix of the *EGFR* tyrosine kinase domain. These findings are consistent with the results of Yasuda et al. \[[@b17-crt-2018-151]\]. We observed three novel amino acid sequence variants: Pro772_His773insGlyAsnPro, Val769_Asn771insValGlyVal, and Pro772_His773insThrThr-Pro. This suggests that exon 20 insertion mutations are highly variable and heterogeneous. Although the clinical significance of these novel sequences has not been established, efforts to find new amino acid sequences in exon 20 mutations are warranted.

It has been suggested that exon 20 insertions and other types of *EGFR* mutations are mutually exclusive \[[@b11-crt-2018-151]-[@b14-crt-2018-151],[@b16-crt-2018-151]\]. Among the 56 patients with exon 20 insertions in our study, eight had an additional *EGFR* mutation to the exon 20 insertion, such as L858R, an exon 19 deletion, S768I, or G719S. Patients with a double mutation comprising an exon 20 insertion and L858R or G719S initially achieved a partial response to EGFR TKIs. However, the PFS was short (1.9-2.9 months), suggesting that exon 20 insertion might be dominant over the other more common mutation. Further validation of these results is needed. As expected, patients with an exon 20 insertion only who received EGFR TKIs had a low response rate and short PFS (\~2.6 months; range, 0.7 to 11.4), consistent with previous reports \[[@b12-crt-2018-151],[@b14-crt-2018-151],[@b15-crt-2018-151],[@b20-crt-2018-151]\].

One patient showed a long duration of stable disease following treatment with an *EGFR* TKI. Some exon 20 insertions (such as A763_Y764insFQEA) are relatively sensitive to *EGFR* TKIs, and this patient may have had such a variant \[[@b12-crt-2018-151],[@b21-crt-2018-151]\].

In general, exon 20 insertion mutation in NSCLC is associated with lack of sensitivity to first-generation *EGFR* TKIs, such as erlotinib or gefitinib \[[@b12-crt-2018-151]-[@b14-crt-2018-151],[@b18-crt-2018-151],[@b19-crt-2018-151]\], and so does our study ([Table 5](#t5-crt-2018-151){ref-type="table"}). The exact mechanism underlying this lack of sensitivity has not been fully established. It is possible that exon 20 insertions occurring after the C-helix might induce conformational changes that affect the binding affinity to *EGFR* inhibitors, promoting resistance to EGFR TKIs \[[@b17-crt-2018-151]\]. Kosaka et al. showed that replacing Asp770 with Gly770 restored sensitivity to EGFR TKIs by allowing Arg776 access. This facilitated a C-helix conformational change and substrate binding in Ba/F3 cells transduced with an *EGFR* exon 20 insertion mutation \[[@b22-crt-2018-151]\].

In one pre-clinical study, patient derived xenografts cells harboring an *EGFR* exon 20 insertion showed a partial response to second-generation (afatinib) and third-generation (osimertinib and rociletinib) TKIs \[[@b23-crt-2018-151]\]. Another pre-clinical study showed that a novel, mutant-selective inhibitor of *EGFR* (nazartinib) showed promising results *in vitro* in cancer-derived cell lines expressing exon 20 insertions. Nazartinib was effective for the duration of the therapeutic window, at only half the maximal inhibitory concentration (IC~50~) \[[@b24-crt-2018-151]\]. But in clinical trials to date, promising results have not been observed with currently available agents designed to target *EGFR* \[[@b25-crt-2018-151],[@b26-crt-2018-151]\]. Therefore, further studies are needed to enhance our understanding of the *EGFR* structure and to clarify the mechanisms by which exon 20 insertions affect patient responses to *EGFR* TKIs. As part of these efforts, one phase II study of poziotinib in patients with advanced NSCLC and *EGFR* exon 20 mutations had been conducted. In this study, seven of 11 patients achieved a partial response to poziotinib, suggesting its promising efficacy \[[@b27-crt-2018-151]\].

In this study, the advanced NSCLC patients with exon 20 insertion had median OS of 29.4 months (95% CI, 9.3 to 49.6), which is consistent with median OS of advanced NSCLC with common *EGFR* mutations \[[@b8-crt-2018-151],[@b9-crt-2018-151]\]. The ORR and PFS to platinum-based chemotherapy were 50% and 4.2 months, respectively. Considering the poor outcomes with EGFR TKIs, platinum-based systemic chemotherapy is considered standard treatment for advanced NSCLC with an exon 20 insertion mutation \[[@b12-crt-2018-151],[@b20-crt-2018-151]\].

The present study has certain limitations. Given the small number of patients and retrospective nature of the analysis, patients analyzed in this cohort might not be representative of all types of advanced NSCLC with *EGFR* exon 20 insertion mutations. Furthermore, the various techniques used in this study to detect *EGFR* mutations have inherently different levels of specificity and sensitivity. Nevertheless, we analyzed one of the largest cohorts of its kind, with more than 3,000 patients with activating *EGFR* mutations.

In conclusion, exon 20 insertion mutations are rare in Korea, and are occasionally accompanied by common *EGFR* mutations. Although the response to systemic chemotherapy in these patients is comparable to that in patients with more common *EGFR* mutations, the response rate to first- or second-generation EGFR TKIs is quite low. For this reason, the development of a more efficient chemotherapeutic agent is urgently needed.
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###### 

Clinical characteristics of total 3,539 patients with NSCLC

                              Common (n=3,163)   Uncommon (n=376)   p-value
  --------------------------- ------------------ ------------------ ----------
  **Age at diagnosis (yr)**   61 (19-92)         62 (27-87)         NS
  **Sex**                                                           
   Female                     2,008 (63.5)       217 (57.7)         0.032
   Male                       1,155 (36.5)       159 (42.3)         
  **Histology**                                                     
   ADC                        3,077 (97.3)       335 (89.1)         \< 0.001
   SqCC                       47 (1.5)           20 (5.3)           
   Others                     39 (1.2)           21 (5.6)           
  **Stage**                                                         
   I-IIIA                     1,866 (59.0)       194 (51.6)         0.007
   IIIB-IV                    1,297 (41.0)       182 (48.4)         

Values are presented as median (range) or number (%). NSCLC, non-small cell lung cancer; NS, non-significant; ADC, adenocarcinoma; SqCC, squamous cell carcinoma.

###### 

Baseline characteristics of patients with an exon 20 insertion mutation

                              Early-stage (n=29)   Refractory NSCLC (n=27)   Total (n=56)
  --------------------------- -------------------- ------------------------- --------------
  **Age at diagnosis (yr)**   60 (36-78)           60 (43-75)                60 (36-78)
  **Sex**                                                                    
   Female                     14 (48.2)            11 (40.7)                 25 (44.6)
   Male                       15 (51.8)            16 (59.3)                 33 (55.4)
  **Histology**                                                              
   ADC                        29 (100)             26 (96.3)                 55 (98.2)
   SqCC                       0                    1 (3.7)                   1 (1.8)
  **ECOG**                                                                   
   0                          8 (27.6)             1 (3.8)                   9 (16.1)
   1                          21 (72.4)            19 (70.3)                 40 (71.4)
   2                          0                    7 (25.9)                  7 (12.5)
  **Smoking history**                                                        
   Never                      19 (65.5)            21 (77.8)                 40 (71.4)
   Current                    6 (20.7)             3 (11.1)                  9 (16)
   Ex                         4 (13.8)             3 (11.1)                  7 (12.6)
  **Metastasis**                                                             
   CNS                        \-                   11                        \-
   Bone                       \-                   9                         \-
   Liver                      \-                   5                         \-
   Lung                       \-                   9                         \-
  **Exon 20 mutation**                                                       
   Insertion only             25 (8-6.2)           23 (85.2)                 \-
  **Double mutation**                                                        
   Insertion+S768I            \-                   1 (3.7)                   \-
   Insertion+G719S            \-                   1 (3.7)                   \-
   Insertion+Deletion 19      4 (13.8)             \-                        \-
   Insertion+L858R            \-                   2 (7.4)                   \-

Values are presented as median (range) or number (%). NSCLC, non-small cell lung cancer; ADC, adenocarcinoma; SqCC, squamous cell carcinoma; ECOG, Eastern Cooperative Oncology Group; CNS, central nervous system.

###### 

Amino acid sequences of 17 NSCLC patients with an exon 20 insertion

  No.   Sex   Age (yr)   Smoking Hx   ECOG   Initial stage   Exon 20 mutation                                EGFR TKI   Chemotherapy            Best response   PFS    OS
  ----- ----- ---------- ------------ ------ --------------- ----------------------------------------------- ---------- ----------------------- --------------- ------ ------
  1     F     58         Never        1      IIIA            c.2319_2320 ins CAC (p.H773_V774insH)           N/A        Premetrexed+cisplatin   SD              17.0   46.4
  2     M     73         Never        2      IA              c.2319_2320 ins CAC (p.H773_V774insH)           N/A        N/A                                            44.8
  3     M     75         Never        1      IV              C.2316_2317 ins GGCAACCCC (p.P772_H773insGNP)   N/A        Premetrexed+cisplatin   SD              2.7    3.8
  4     M     63         Never        1      IIIA            c.2319_2320 ins CCCCAC (p.H773_V774insH)        N/A        Paclitaxel+cisplatin    PD              0.9    9.7
  5     M     50         Never        1      IB              c.2305_2313 ins GTGGGGGTC (p.V769_N771insVGV)   N/A        N/A                                            22.5
  6     F     55         Never        1      IV              c.2310_2311 ins GGT (p.D770_N771insG)           N/A        Premetrexed+cisplatin   PD              1.9    6.1
  7     F     63         Never        2      IV              c.2322_2323 ins CACGTG (p.V774_C775insHV)       N/A        Premetrexed+cisplatin   SD              2.1    18.4
  8     F     55         Never        1      IA              c.2322_2323 ins CACGTG (p.V774_C775insHV)       N/A        Premetrexed+cisplatin   PR              13.0   26.2
  9     F     56         Never        1      IIIA            c.2319_2320 ins AACCCCCAC (p.H773_V774insNPH)   N/A        Docetaxel+cisplatin     PR              2.7    29.5
  10    M     60         Never        2      IB              c.2319_2320 ins CCCCAC (p.H773_V774insPH        N/A        Premetrexed+cisplatin   PR              2.6    46.4
  11    M     48         Never        2      IV              c.2315_2316 ins GACAACCCC (p.P772_H773insTTP)   N/A        Premetrexed+cisplatin   PR              2.4    12.4
  12    F     62         Never        1      IA              c.2321_2322 ins CCACGT (p.V774_C775insHV)       N/A        N/A                                            44.1
  13    F     52         Never        1      IA              c.2319_2320insCAC (p.H773_V774insH)             N/A        N/A                                            35.2
  14    M     60         Never        1      IIIA            c.2319_2320insCAC (p.H773_V774insH)             N/A        Etoposide+cisplatin     PD              2.6    25.9
  15    M     60         Never        1      IIIA            c.2319_2320insCAC (p.H773_V774insH)             N/A        Etoposide+cisplatin     SD              17.2   26.2
  16    F     66         Never        1      IIIA            c.2318_2319 ins TAACCCCAG (p.H773_V774insPH)    N/A        Premetrexed+cisplatin   SD              2.8    62.4
  17    M     65         Never        1      IA              c.2319_2320insCAC (p.H773_V774insH)             N/A        Premetrexed+cisplatin   PR              2.9    36.9

The most frequent amino acid change was His773_Val774insHis (41.1%), followed by Val774_Cys775insHisVal (17.6%) and His773_Val774insProHis (11.7%).

NSCLC, non-small cell lung cancer; ECOG, Eastern Cooperative Oncology Group; ECOG, Eastern Cooperative Oncology Group; EGFR TKI, epidermal growth factor receptor tyrosine kinase inhibitor; PFS, progression-free survival; OS, overall survival; F, female; N/A, not available; M, male; SD, stable disease; PD, progressive disease; PR, partial response.

###### 

Clinical information and treatment outcomes of six patients who received EGFR TKIs

  Sex   Age (yr)   Exon 20 type      ECOG   Smoking history       Initial stage   TKI type      EGFR TKI response   PFS
  ----- ---------- ----------------- ------ --------------------- --------------- ------------- ------------------- ------
  F     44         Insertion         1      Never-smoker          IV              Erlotinib     PD                  0.7
  M     65         Insertion         2      Never-smoker          IV              Afatinib      PD                  0.9
  M     60         Insertion         1      Current smoker 30PY   IV              Erlotinib     PD                  2.6
  M     48         Insertion         0      Ex-smoker 20PY        IV              Erlotinib     SD                  11.4
  M     62         Insertion+L858R   1      Ex-smoker 10PY        IIB             Afatinib      PR                  1.9
  F     43         Insertion+G719S   1      Never-smoker          IV              Osimertinib   PR                  2.8

EGFR TKI, epidermal growth factor receptor tyrosine kinase inhibitor; ECOG, Eastern Cooperative Oncology Group; PFS, progression-free survival; F, female; M, male; PD, progressive disease; SD, stable disease; PR, partial response.

###### 

Published studies evaluating clinical response to EGFR TKIs in NSCLC patients with exon 20 insertion

  Study                                         Type of EGFR Exon 20 mutation   Patients treated with EGFR TKIs   ORR to TKI (%)   PFS to TKI       OS
  --------------------------------------------- ------------------------------- --------------------------------- ---------------- ---------------- -----------------
  Tu et al. \[[@b18-crt-2018-151]\]             Insertion 20                    12                                0                3.0 (1.3-4.7)    12.5 (0-25.5)
  Lund-Iversen et al. \[[@b13-crt-2018-151]\]   Insertion 20                    3                                 0                \-               \-
  Arcila et al. \[[@b15-crt-2018-151]\]         Insertion 20                    5                                 40               2.5              \> 48 mo
  Naidoo et al. \[[@b12-crt-2018-151]\]         Insertion 20                    11                                27               \-               \-
  Yasuda et al. \[[@b17-crt-2018-151]\]         Insertion 20                    19                                11               \-               \-
  Kuiper et al. \[[@b19-crt-2018-151]\]         Insertion 20                    16                                0                2.9 (2.3-3.6)    9.7
  Current study                                 Insertion 20                    4                                 25               2.6 (0.7-11.4)   29.4 (9.3-49.6)

EGFR TKI, epidermal growth factor receptor tyrosine kinase inhibitor; NSCLC, non-small cell lung cancer; ORR, objective response rate; PFS, progression free survival; OS, overall survival.
